Insights

Nebido, a long-acting injectable testosterone widely used globally, is expected to enter the Canadian market. With dosing every 10–14 weeks, it adds a new treatment pathway to a system that has struggled for years with recurring shortages of testosterone cypionate and enanthate. It could reduce some pressure by spreading demand and lowering how often patients need refills. The key question is whether the system can absorb this new option in a way that improves access, or whether Nebido will sit alongside the same supply issues patients already face. Read more »

Testosterone shortages in Canada have been recurring for more than a decade, driven by a fragile supply system with limited flexibility and few manufacturers. At the same time, virtual TRT clinics, with streamlined prescribing and home delivery, have made testosterone easier to access and stay on. As access continues to expand, the issue is no longer whether testosterone shortages will happen, but how often they occur, how long they last, and how many people are affected. Read more »

Depo-Testosterone, manufactured by Pfizer, had been a core injectable testosterone product in Canada since the 1950s. After years of recurring shortages and unstable supply, Pfizer exited the market in 2025. What looked like a single product disappearing was part of a longer pattern — and it left Canada with limited backup across just two manufacturers for injectable testosterone. Read more »